DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...
WeDriveU Customers Named Best Workplaces and Best Universities for Commuters in 2025 WeDriveU logo Annual award program honors emplo ...